The use of continuous glucose monitoring has been suggested as a method of determining glucose control in prediabetes, including understanding glucose variability, which may be a risk factor in the progression to type 2 diabetes. This pilot research study aimed to determine glycemic variability (%CV) in people diagnosed with impaired glucose tolerance (IGT)/prediabetes. The study included people aged 18 or over, with their most recent HbA1c 5.7-6.4% (39-47 mmol/mol) recorded in medical notes in the last 12 months. Pregnant patients were excluded, as were patients with diabetes. A total of 43 participants (60.5% female) from 5 primary care sites in the UK enrolled in the 2-week single arm study, wearing a FreeStyle Libre Pro Flash Glucose Monitoring SystemTM (glucose data was not available to participants). On average, HbA1c was 6.06±0.25% (42.7±2.6 mmol/mol), age was 62.5±8.3 years, BMI was 32.1±6.6 kg/m2, average time since diagnosis was 18±19 months, average Q diabetes score was 28.4±23.7% (mean±SD). Glucose variability (%CV) was 17.3±3.8%, %CV was greater during daytime hours (06:00 to 23:00) than at night (23:00 to 06:00), 17.7±4.1% and 12.9±3.5% respectively (mean±SD). %CV was greater in those with BMI<30 kg/m2 compared to those ≥30 kg/m2; 18.9±3.3% and 15.8±3.5% respectively (mean±SD). Mean glucose was 101.2±10.0 mg/dL, time in hyperglycemia (>180 mg/dL, 10.0 mmol/L) was 0.09±0.23 hours per day (mean±SD). Ten anticipated sensor insertion site symptoms were experienced by five participants: erythema (n=2, well-defined redness), pain (n=1), bruising (n=1), itching (n=2), rash (n=2), bleeding (n=1) and other (n=1, ‘skin irritation’), all were mild in severity and resolved. This population, with prediabetes experienced glucose variability of 17.3% (%CV). This was greater during daytime hours and in those with lower BMI (<30 kg/m2).
K. Douglas: None. N. Annamalai: None. P.J. Moore: None. S. Thomson: Research Support; Self; Abbott. Research Support; Spouse/Partner; Abbott.